Secukinumab is a human monoclonal antibody that neutralizes IL-17A to inhibit the inhibitor kappa B alpha (IκBα) /NF-κB pathway, reduce IκBα and NF-κB phosphorylation levels, inhibit the expression of pro-inflammatory factors (i.e., IL-6 and TNF-α), and improve the inflammatory response and lung injury induced by sepsis. The gene discussed is NFKB1; the disease is Sepsis.